This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-06. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The main Imperial Russian Army was commanded by Field Marshal Michael Andreas Barclay de Tolly, who recognized that Napoleon's immediate goal was a decisive battle to crush the main Russian force in the west. In response, the Russian army used scorched-earth tactics as it withdrew east, and harried the Grande Armée with light Cossack cavalry. The Grande Armée did not adjust its operational methods in response. Provisioning such an enormous army with adequate food and fresh water had proven difficult since the very start of the campaign, exacerbated by the sparse terrain of western Russia; diseases such as typhus and dysentery rapidly became rampant among the rank and file. These factors led to most of the losses of the main column of the Grande Armée, which in one case amounted to 95,000 men, including deserters, in a week. The main Russian army retreated for almost three months. This constant retreat led to the increasing unpopularity of Barclay de Tolly (who was a Baltic German and already mistrusted by the Russian elite) and a respected Russian veteran, Prince Mikhail Kutuzov, was made the new Commander-in-Chief by Tsar Alexander. Finally, the two armies engaged in the Battle of Borodino on 7 September, in the vicinity of Moscow. The battle was the largest and bloodiest single-day action of the Napoleonic Wars, involving more than 250,000 men and resulting in at least 70,000 casualties. The battle was indecisive; the French captured the main positions on the battlefield but failed to destroy the Russian army.
== Treatment == Ciguatera poisoning is a treatable condition. Genetically susceptible individuals can develop a long-term illness due to inability to clear the Ciguatera toxins; these people can be treated using the protocol for Chronic Inflammatory Response Syndrome (CIRS). Acutely, the mainstay of treatment is supportive care, but once the toxin is identified, CIRS treatment should start as soon as possible, as it will speed recovery, even for those without the genetic susceptibility. There is some evidence that calcium channel blockers like nifedipine and verapamil are effective in treating some of the symptoms that remain after the initial sickness passes, such as poor circulation and shooting pains through the chest. These symptoms are due to vasoconstriction caused by maitotoxin and/or palytoxin. Ciguatoxin lowers the threshold for opening voltage-gated sodium channels in synapses of the nervous system. Opening a sodium channel causes depolarization, which could sequentially cause paralysis, vasoconstriction, and changing the senses of hot and cold. Some medications such as amitriptyline may reduce some symptoms, such as fatigue and paresthesia, although benefit does not occur in every case.
Burkholderia pseudomallei (also known as Pseudomonas pseudomallei) is a Gram-negative, bipolar, aerobic, motile rod-shaped bacterium. It is a soil-dwelling bacterium endemic in tropical and subtropical regions worldwide, particularly in Thailand and northern Australia. It was reported in 2008 that there had been an expansion of the affected regions due to significant natural disasters, and it could be found in Southern China, Hong Kong, and countries in the Americas. B. pseudomallei, amongst other pathogens, has been found in monkeys imported into the United States from Asia for laboratory use, posing a risk that the pathogen could be introduced into the country. Although it is mainly a soil-dwelling bacterium, one study showed that Burkholderia pseudomallei survived in distilled water for 16 years, demonstrating that it is capable of living in water if a specific environment is provided. It is resistant to a variety of harsh conditions including nutrient deficiency, extreme temperature or pH. It infects humans, causing the disease melioidosis; mortality is 20–50% even with treatment. The CDC classifies it as a "Tier 1 select agent" with potential as a bioterrorism agent. It infects other animals, most commonly livestock such as goats, pigs, and sheep, less frequently. It is also capable of infecting plants in a laboratory setting. Burkholderia pseudomallei measures 2–5 μm in length and 0.4–0.8 μm in diameter and is capable of self-propulsion using flagella.
=== Wort cooling === After the whirlpool, the wort is cooled to the appropriate fermentation temperature before being transferred to the fermentation area. In modern breweries this is achieved through a plate heat exchanger. A plate heat exchanger has several ridged plates, which form two separate paths. The wort is pumped into the heat exchanger and goes through every other gap between the plates. The cooling medium, usually water from a cold liquor tank, goes through the other gaps. The ridges in the plates ensure turbulent flow. Wort is typically cooled in a plate heat exchanger from near boiling point to the appropriate pitching temperature. Cooling may use a single-stage system with chilled water, or a multi-stage system using water followed by a secondary coolant such as glycol. After cooling, the wort is oxygenated before fermentation to provide oxygen required for yeast development. While boiling, it is useful to recover some of the energy used to boil the wort. On its way out of the brewery, the steam created during the boil is passed over a coil through which unheated water flows. By adjusting the rate of flow, the output temperature of the water can be controlled. This is also often done using a plate heat exchanger. The water is then stored for later use in the next mash, in equipment cleaning, or wherever necessary. Another common method of energy recovery takes place during the wort cooling. When cold water is used to cool the wort in a heat exchanger, the water is significantly warmed.
=== Celebrity protests of business expansion === In 2006, Paul McCartney protested a proposed $175 million animal testing laboratory by the company in Chandler, Arizona. However, the laboratory opened in 2009.
Sources: en.wikipedia.org
== External links == IPC – Isoelectric Point Calculator — calculate protein isoelectric point using over 15 methods prot pi – protein isoelectric point — an online program for calculating pI of proteins (include multiple subunits and posttranslational modifications) CurTiPot — a suite of spreadsheets for computing acid-base equilibria (charge versus pH plot of amphoteric molecules e.g., amino acids) pICalculax — Isoelectric point (pI) predictor for chemically modified peptides and proteins SWISS-2DPAGE Archived 2016-12-10 at the Wayback Machine — a database of isoelectric points coming from two-dimensional polyacrylamide gel electrophoresis (~ 2,000 proteins) PIP-DB — a Protein Isoelectric Point database (~ 5,000 proteins) Proteome-pI — a proteome isoelectric point database (predicted isoelectric point for all proteins)
precipitation The process of producing a separable solid phase within a liquid medium, e.g. by transforming the dissolved solute of a supersaturated solution into an insoluble solid; or the diffusion of a distinct solid phase out of a solid alloy. A reagent that causes such a reaction is called the precipitant, and the separable solid itself is the precipitate. More generally, the term may refer to the formation of any new condensed phase by changing the physical properties of a system (e.g. water vapor condensing into liquid water droplets).
As of January 2026, there were 575 federally recognized tribes. There are approximately 326 Indian reservations. The tribes hold a government-to-government relationship with the U.S. federal government in Washington and are legally defined as domestic dependent nations with inherent tribal sovereignty rights. In addition to the five major territories, the U.S. also asserts sovereignty over the United States Minor Outlying Islands in the Pacific Ocean and the Caribbean. The seven undisputed islands without permanent populations are Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Atoll, and Palmyra Atoll. U.S. sovereignty over the unpopulated Bajo Nuevo Bank, Navassa Island, Serranilla Bank, and Wake Island is disputed.
=== Assistive technologies === Assistive technologies are products designed to provide accessibility to individuals who have physical or cognitive problems or disabilities. They aim to improve the quality of life with assistive technologies. The range of assistive technologies is broad, ranging from low-tech solutions to physical hardware, to technical devices. There are four areas of assistive technologies, which include visual impairment, hearing impairment, physical limitations, cognitive limitations. There are many benefits of assistive technologies. They enable individuals to care for themselves, work, study, access information easily, improve independence and communication, and lastly participate fully in community life.
Nordazepam and other sedative–hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Many drivers have blood levels far exceeding the therapeutic dose range, suggesting benzodiazepines are commonly used in doses higher than the recommended doses.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.